Lrrk2-mediated Neuronal Toxicity

Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease.

Patents:
WO 2,011,057,204

Inventor(s): LEE BYOUNG DAE [US]; DAWSON TED M [US]; DAWSON VALINA L [US]; WEST ANDREW B [US]

Type of Offer: Licensing



Next Patent »
« More Medical Patents

Share on      


CrowdSell Your Patent